Skip to main content
SpringerLink
Log in

Drug Therapy

  • Chapter
Osteoporosis

Part of the book series: Current Clinical Practice ((CCP))

Abstract

Previous chapters have reviewed the importance of lifestyle changes, adequacy of calcium and vitamin D stores, and the use of hormone replacement therapy for the prevention and treatment of osteoporosis. The recent burgeoning interest in osteoporosis stems not only from an increased awareness of women’s health issues and the important effects of lifestyle on health, but also from the related explosion of knowledge about the pathophysiology of osteoporosis. This has been the result of advances in basic science, new noninvasive techniques for measuring bone turnover and bone density, and the development of many new promising drugs for the prevention and treatment of bone loss (1-4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Recker RR. Current therapy for osteoporosis.J Clin Endocrinol Metab1993; 76: 14–16.

    Article  PubMed  CAS  Google Scholar 

  2. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis.Am JMed1993; 94: 646–650.

    Google Scholar 

  3. Rodan GA. Emerging therapies in osteoporosis.Ann Rep Med Chem1994; 29: 275–285.

    Article  CAS  Google Scholar 

  4. Reginster JY. Treatment of bone in elderly subjects: calcium, vitamin D, fluor, bisphosphonates, calcitonin.Horm Res1995; 43: 83–88.

    Article  PubMed  CAS  Google Scholar 

  5. Cooper C, Kanis JA, Compston J. How to assess drug efficacy in osteoporosis.Lancet1995; 345: 743–744.

    Article  PubMed  CAS  Google Scholar 

  6. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis.NEngl JMed1992; 327: 620–627.

    Article  CAS  Google Scholar 

  7. Civitelli R, Gonnelll S, Zacchei F, et al. Bone turnover or postmenopausal osteoporosis. Effect of calcitonin treatment.J Clin Invest1988; 82: 1268–1274.

    Article  PubMed  CAS  Google Scholar 

  8. Kleerekoper M. Extensive personal experience: the clinical evaluation and management of osteoporosis.J Clin Endocrinol Metab1995; 80: 757–763.

    Article  PubMed  CAS  Google Scholar 

  9. Eriksen EF, Brixen K, Charles P. New markers of bone metabolism: clinical use in metabolic bone disease.Eur J Endocrinol1995; 132: 251–263.

    Article  PubMed  CAS  Google Scholar 

  10. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series WHO, Geneva 1994.

    Google Scholar 

  11. Melton LJ III, Atkinson EJ, O’Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites.J Bone Miner Res1993; 8: 1227–1233.

    Article  PubMed  Google Scholar 

  12. Silman AJ. The patient with fracture: the risk of subsequent fracture.Am J Med1995; 98 (suppl 2A): 12S–16S.

    Article  PubMed  CAS  Google Scholar 

  13. McDermott MT, Kidd GS. The role of calcitonin in the development and treatment of osteoporosis.Endocr Rev1987; 8: 377–390.

    Article  PubMed  CAS  Google Scholar 

  14. Carstens JH Jr, Feinblatt JD. Future horizons for calcitonin: a U.S. perspective.Calcif Tissue Int1991; 49 (suppl 2): S2–S6.

    Article  PubMed  Google Scholar 

  15. Reginster JY. Effect of calcitonin on bone mass and fracture rates.Am JMed1991; 91 (suppl 5B): 19S–22S.

    CAS  Google Scholar 

  16. Avioli LV. Calcitonin in the prevention and therapy of osteoporotic syndromes.EndocrPract1995; 1: 33–38.

    CAS  Google Scholar 

  17. Gruber HE, Ivey JL, Baylink DJ, et al. Long-term calcitonin therapy in postmenopausal women.Metabolism1984; 33: 295–303.

    Article  PubMed  CAS  Google Scholar 

  18. Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis.Curr Ther Res1985; 38: 455–464.

    Google Scholar 

  19. Mazzuoli GF, Passer’ M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.Calcif Tissue Int1986; 38: 3–8.

    Article  PubMed  CAS  Google Scholar 

  20. Overgaard K, Riis Bi, Christiansen C, et al. Effects of salcatonin given intranasally on early postmenopausal bone loss.BMJ1989; 299: 477–479.

    Article  PubMed  CAS  Google Scholar 

  21. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.Calcif Tissue Int1994; 56: 82–86.

    Article  Google Scholar 

  22. Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. EurJ Clin Invest1994; 24: 565–569.

    Article  PubMed  CAS  Google Scholar 

  23. Lyritis GP, Magiasis B, Tsakalakos N. Prevention of bone loss; in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment.Calcif Tissue Int1995; 56: 38–41.

    Article  PubMed  CAS  Google Scholar 

  24. Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal calcitonin for prevention of postmenopausal lumbar spine bone loss.Am JMed1995; 98: 452–458.

    CAS  Google Scholar 

  25. Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis.Clin Endocrinol1989; 30: 435–442.

    Article  CAS  Google Scholar 

  26. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ1992; 305: 556–561.

    Article  PubMed  CAS  Google Scholar 

  27. Campodarve I, Drinkwater BL, Insogna KL, et al. Intranasal salmon calcitonin (INSC) 50–200 IU does not prevent bone loss in early postmenopausal women. 1994;J Bone Miner Res9 (suppl 1): S391 (abstract).

    Google Scholar 

  28. Rico H, Hernandez ER, Revilla M, et al. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome.Bone Miner1992; 16: 131–138.

    Article  PubMed  CAS  Google Scholar 

  29. Rico H, Revilla M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.Calcif Tissue Int1995; 56: 181–185.

    Article  PubMed  CAS  Google Scholar 

  30. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.BMJ1992; 305: 1124–1128.

    Article  PubMed  CAS  Google Scholar 

  31. Wimalawansa SJ. Long-and short-term side effects and safety of calcitonin in man: a prospective study.Calcif Tissue Int1993; 52: 90–93.

    Article  PubMed  CAS  Google Scholar 

  32. Wallach S, Farley JR, Baylink DJ, et al. Effects of calcitonin on bone quality and osteoblastic function.Calcif Tissue Int1993; 52: 335–339.

    Article  PubMed  CAS  Google Scholar 

  33. Reginster JY, Albert A, Lecart MP, et al. 1-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin.Lancet1987; ii: 1481–1483.

    Article  Google Scholar 

  34. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study.Calcif Tissue Int1991; 49: 369–372.

    Article  PubMed  CAS  Google Scholar 

  35. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures.Clin Ther1989; 11: 205–209.

    PubMed  CAS  Google Scholar 

  36. Drug Topics Red Book 1995; Medical Economics, Montvale, NJ.

    Google Scholar 

  37. Lombardi A, Santora AC. Clinical trials with bisphosphonates.Bone Miner 1993;22 (suppl): S59–S70.

    Google Scholar 

  38. Ott S. Clinical effects of bisphosphonates in involutional osteoporosis.J Bone Miner Res1993; 8 (suppl 2): S597–S606.

    Article  PubMed  Google Scholar 

  39. Fleisch H. New bisphosphonates in osteoporosis.Osteoporosis Int1993; 2 (suppl): S15–S22.

    Article  Google Scholar 

  40. Compston JE. The therapeutic use of bisphosphonates.BMJ1994; 309: 711–715.

    Article  PubMed  CAS  Google Scholar 

  41. Bijvoet OLM, Valkema R, Lowik CWGM, et al. Bisphosphonates in osteoporosis?Osteoporosis Int1993; 1 (suppl): S230–S236.

    Article  Google Scholar 

  42. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclinical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.N Engl J Med1990; 322: 1265–1271.

    Article  PubMed  CAS  Google Scholar 

  43. Storm T, Steiniche T, Thamsborg G, et al. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.JBoneMiner Res1993; 8: 199–208.

    CAS  Google Scholar 

  44. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.NEngl JMed1990; 327: 73–79.

    Article  Google Scholar 

  45. Ott SM, Woodson GC, Huffer WE, et al. Bone histomorphometric change after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.J Clin Endocrinol Metab1994; 78: 968–972.

    Article  PubMed  CAS  Google Scholar 

  46. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis. Three years of blinded therapy followed by one year of open therapy.Am JMed1993; 95: 557–567.

    CAS  Google Scholar 

  47. Kanis JA, Gertz BJ., Singer F, et al. Rationale for the use of alendronate in osteoporosis.Osteoporosis Int1995; 5: 1–13.

    Article  Google Scholar 

  48. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.Am JMed1995; 99: 144–152.

    CAS  Google Scholar 

  49. Seeman E, Nagant de Deuxchaisnes C, Meunier P, et al. Treatment of postmenopausal osteoporosis with oral alendronate.Bone1995; 16 (suppl 1): 1205 (abstract).

    Google Scholar 

  50. Liberman UA, Weiss SR, Broil J, et al. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.N Engl J Med1995; 1437–1443.

    Google Scholar 

  51. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.J Clin Invest 1993;92: 2577–2586.

    Article  PubMed  CAS  Google Scholar 

  52. Reginster JY, Deroisy R, Denis D, et al. Prevention of postmenopausal bone loss by tiludronate.Lancet1989; ii: 1469–1471.

    Article  Google Scholar 

  53. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.J Clin Endocrinol Metab1994; 79: 1595–1599.

    Article  PubMed  CAS  Google Scholar 

  54. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.NEngl JMed1990; 322: 822–809.

    Article  Google Scholar 

  55. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis.Osteoporosis Int1991; 1: 155–161.

    Article  CAS  Google Scholar 

  56. Riggs BL, O’Fallon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis.J Bone Miner Res1994; 9: 265–275.

    Article  PubMed  CAS  Google Scholar 

  57. Pak CYC, Sakhaee K, Adams-Huet B, et al. Treatment ofpostmenopausal osteoporosis with slow-release sodium fluoride.Ann Int Med1995; 123: 401–408.

    PubMed  CAS  Google Scholar 

  58. Love RR, Mazess RB, Barden HS, et al. Effects oftamoxifen on bone mineral density in postmenopausal women with breast cancer.N Engl JMed1992; 326: 852–856.

    Article  CAS  Google Scholar 

  59. Ward RL, Morgan G, Dailey D, et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.Bone Miner1993; 22: 87–94.

    Article  PubMed  CAS  Google Scholar 

  60. Wasnich RD, Benfante RJ, Yano K, et al. Thiazide effect on the mineral content of bone.N Engl. Med1983; 309: 344–347.

    Article  CAS  Google Scholar 

  61. Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls.Ann Int Med 1993;118: 666–673.

    PubMed  CAS  Google Scholar 

  62. LaCroix AZ, Weinpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture.N Engl J Med1990; 322: 286–290.

    Article  PubMed  CAS  Google Scholar 

  63. Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk for hip fracture.Ann Int Med1991; 115: 1–6.

    PubMed  CAS  Google Scholar 

  64. Jones G, Nguyen T, Sambrook ON, et al. Thiazide diuretics and fractures: can meta analysis help?J Bone Miner Res1995; 10: 106–111.

    PubMed  CAS  Google Scholar 

  65. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women.N Engl J Med1992; 327: 1637–1642.

    Article  PubMed  CAS  Google Scholar 

  66. Gallagher JC, Jerpbak CM, Jee WSS, et al. 1,25-dihydroxyvitamin D3: short-and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis.Proc Natl Acad Sci USA1982; 79: 3325–3329.

    Article  PubMed  CAS  Google Scholar 

  67. Riggs BL, Nelson KI. Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis.J Clin Endocrinol Metab1985; 61: 457–461.

    Article  PubMed  CAS  Google Scholar 

  68. Aloia JF, Vaswani A, Yeh JK, et al. Calcitriol in the treatment of postmenopausal osteoporosis.Am J Med1988; 84: 401–408.

    Article  PubMed  CAS  Google Scholar 

  69. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol.Ann Int Med1990; 113: 649–655.

    PubMed  CAS  Google Scholar 

  70. Ott SM, Chesnut CH III. Calcitriol treatment is not effective in postmenopausal osteoporosis.Ann Int Med1989; 110: 267–274.

    PubMed  CAS  Google Scholar 

  71. Tilyard MW, Spears GFS, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium.N Engl J Med1992; 326: 357–362.

    Article  PubMed  CAS  Google Scholar 

  72. Orimo H, Shiraki M, Hayashi Y, et al. Effects of la-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.Calcif Tissue Int1994; 54: 370–376.

    Article  PubMed  CAS  Google Scholar 

  73. Falch JA, Odegaard OR, Finnanger AM, et al. Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol.Acta Med Scand1987; 221: 199–204.

    Article  PubMed  CAS  Google Scholar 

  74. Gallagher JC. Prevention of bone loss in postmenopausal and senile osteoporosis with vitamin D analogues.Osteoporosis Int1993; 1 (suppl): S172–S175.

    Article  Google Scholar 

  75. Riggs BL. Formation-stimulating regimens other than sodium flouride.Am JMed1993; 95 (suppl 5A): 62S–68S.

    CAS  Google Scholar 

  76. Chesnut CH III, Nelp WB, Baylink DJ, et al. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.Metabolism1977; 26: 267–277.

    Article  PubMed  CAS  Google Scholar 

  77. Chesnut CH III, Ivey JL, Gruber HE, et al. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.Metabolism1983; 32: 571–580.

    Article  PubMed  Google Scholar 

  78. Geusens P, Dequeker J. Long-term effect of nandrolone decanoate, l hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoprosis: a double-blind controlled study.Bone Miner1986; 1: 347–357.

    PubMed  CAS  Google Scholar 

  79. Passen M, Pedrazzoni M, Pioli G, et al. Effects of nandralone decanoate on bone mass in established osteoporosis.Maturitas1993; 17: 211–219.

    Article  Google Scholar 

  80. Canalis E. Growth hormone, skeletal growth factors and osteoporosis.Endocr Pract1995; 1: 39–43.

    PubMed  CAS  Google Scholar 

  81. O’Halloran DJ, Tsatsoulis A, Whithouse RW, et al. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency.J Clin Endocrinol Metab1993; 76: 1344–1348.

    Article  PubMed  Google Scholar 

  82. Rudman D, Feller AG, Nagraj HS, et al. Effects of growth hormone in men over 60 years old.N Engl J Med1990; 323: 1–6.

    Article  PubMed  CAS  Google Scholar 

  83. Holloway L, Butterfield G, Hintz FL, Gesundheit N, Marcus R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.J Clin Endocrinol Metab1994; 79: 470–479.

    Article  PubMed  CAS  Google Scholar 

  84. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling.NEngl JMed1995; 332: 305–311.

    Article  CAS  Google Scholar 

  85. Ebeling PR, Jones JD, O’Fallon WM, et al. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women.J Clin Endocrinol Metab1993; 77: 1384–1387.

    Article  PubMed  CAS  Google Scholar 

  86. Lindsay R, Cosman F, Nieves J, et al. A controlled clinical trial of the effects of 1–34 h PTH in estrogen treated osteoporotic women.J Bone Miner Res1993; 8 (suppl 1): S130.

    Google Scholar 

  87. Finkelstein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.NEngl JMed1994; 331: 1618–1623.

    Article  CAS  Google Scholar 

  88. Sebastian A, Harris ST, Ottaway JH, et al. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonatesNEngl JMed1994; 330: 1776–1781.

    Article  CAS  Google Scholar 

  89. Brandi ML. New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs.Am J Med1995 (suppl 5A): 69–74.

    Google Scholar 

  90. Maugeri D, Panebianco P, Russo MS, et al. Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years.Arch Gerontol Geriatr1994; 19: 253–263.

    Article  PubMed  CAS  Google Scholar 

  91. Oursler MJ. Echistatin, a potential new drug for osteoporosis.Endocrinology1993; 132: 939–940 (editorial).

    Article  PubMed  CAS  Google Scholar 

  92. Bell NH, Hollis BW, Shary JR, et al. Diclofenac sodium inhibits bone resorption in postmenopausal women.Am JMed1994; 96: 349–353.

    CAS  Google Scholar 

  93. Black U, Sato M, Rowley ER, et al. Raloxifene (LY 139481 HC 1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.J Cin Invest1994; 93: 63–69.

    Article  CAS  Google Scholar 

  94. Adami S, Baroni MC, Broggini M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.Osteoporosis Im1993; 3 (suppl): 21–27.

    Article  Google Scholar 

  95. McClung MR, Love B, Rosen CT, et al. Evaluation of a new osteoporosis quality of life questionnaire (OQLQ) for women with osteoporosis and back pain. J Bone Miner Res 1995; 10 (suppl 1): S255.

    Google Scholar 

  96. Looker AC, Johnston Jr CC, Wahner HW, et al. Prevalence of low femoral bone density in older US women from NHANES III.J Bone Miner Res1995; 10: 796–802.

    Article  PubMed  CAS  Google Scholar 

  97. Christiansen C. What should be done at the time of menopause?Am JMed1995; 98 (suppl 2A): 56S–59S.

    CAS  Google Scholar 

  98. Kanis JA. Treatment of osteoporosis in elderly women.Am JMed1995; 98 (suppl 2A): 60S–66S.

    CAS  Google Scholar 

  99. Grisso JA, Baum CR, Turner BJ. What do physicians in practice do to prevent osteoporosis?J Bone Miner Res1990; 5: 213–219.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John L. Stock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor, Maine, USA

    Clifford J. Rosen MD

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Stock, J.L. (1996). Drug Therapy. In: Rosen, C.J. (eds) Osteoporosis. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-0221-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-0221-9_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4612-6668-6

  • Online ISBN: 978-1-4612-0221-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation